• 1
    Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277:12931298.
  • 2
    Freedman BI, Iskandar SS, Appel RG. In-depth review: the link between hypertension and nephrosclerosis. Am J Kidney Dis. 1995;25:207221.
  • 3
    Lopes AAS, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white difference in hypertension, non-insulin dependent diabetes, and end-stage renal disease. Am J Kidney Dis. 1995;25:350356.
  • 4
    Wright JT Jr, Kuzek JW, Toto RD, et al. Design and baseline characteristics in African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17(suppl 4):3S16S.
  • 5
    Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis. 1997;29:720728.
  • 6
    Agodoa LY, Appel L, Bakris G, et al., for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:27192728.
  • 7
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685693.
  • 8
    Ruggenenti P, Gaspari F, Perna A, et al. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patients without diabetes. BMJ. 1998;316:504509.
  • 9
    Giatras I, Lau J, Levey AS, for the Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997;127:337345.
  • 10
    Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939945.
  • 11
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:14561462.
  • 12
    Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352:12521256.
  • 13
    Klahr S, Levey AS, Beck GJ, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754762.
  • 14
    Rodby RA, Rohde RD, Clarke WR, et al., for the Collaborative Study Group. The irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. Nephrol Dial Transplant. 2000;15:487497.
  • 15
    Brenner BM, Cooper ME, De Zeeuw D, et al. The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J RAS. 2000;1:328335.
  • 16
    Sica DA. The Heart Outcomes Prevention Evaluation (HOPE) Study: limitations and strengths. J Clin Hypertens. 2000;2:406414.
  • 17
    Johnston CI, Risvanis J, Naitoh M, et al. Mechanism of progression of renal disease: current hemodynamic concepts. J Hypertens. 1998;16(suppl):S3S7.
  • 18
    Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis. 2001;37(suppl 2):S21S24.
  • 19
    Wolf G. Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant. 1998;13:11311142.
  • 20
    Abbate M, Remuzzi G. Proteinuria as a mediator of tubulointerstitial injury. Kidney Blood Press Res. 1999;22:3746.
  • 21
    Bakris GL, Williams M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646661.
  • 22
    Marre M. Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases. Am J Hypertens. 1998;11:884886.
  • 23
    Flack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin. 2000; 16:6679.
  • 24
    Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354:359364.
  • 25
    Kloke HJ, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 1998;53:15591573.
  • 26
    Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54: 12831289.